• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Conformis misses on Q4 results

Conformis misses on Q4 results

March 3, 2022 By Sean Whooley

ConformisConformis (NSDQ:CFMS) shares closed slightly down today on fourth-quarter results that missed the consensus forecast.

The Billerica, Massachusetts-based company posted losses of nearly $16 million, or 9¢ per share, on sales of $15.3 million for the three months ended Dec. 31, 2021, for a large bottom-line slide deeper into the red on a sales decline of 7.6%.

Conformis’ losses per share of 9¢ fell 2¢ shy of expectations on Wall Street, where analysts were looking for sales of $15.6 million.

The company recently launched its Platinum Services Program, which represents a first in orthopedics and aims to complement the Imprint knee system, which Conformis expects will advance to full market release later this year.

“With all of the recent development initiatives in place as we head into 2022, we are poised for growth,” Conformis CEO Mark Augusti said in a news release. “The pace of our growth will likely correlate to how fast medical facilities resume normal operations as the impact from the omicron variant of COVID-19 fades and staffing levels bounce back.”

The company projects first-quarter product revenue to range between $13.5 million and $14.5 million. That outlook reflects the continued disruption of elective procedures caused by the omicron variant, as well as COVID-19’s potential impact on existing scheduled surgeries, staffing shortages in medical facilities, and manufacturing capacity challenges due to Conformis’ own staffing issues.

CFMS shares were down slightly at 67¢ per share at the close of trading. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was also down slightly.

Filed Under: Business/Financial News, Featured, Implants, MassDevice Earnings Roundup, News Well, Orthopedics, Wall Street Beat Tagged With: conformis

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy